Effect of Apheresis for ABO and HLA Desensitization on Anti-Measles Antibody Titers in Renal Transplantation
- PMID: 22174988
- PMCID: PMC3235902
- DOI: 10.1155/2011/869065
Effect of Apheresis for ABO and HLA Desensitization on Anti-Measles Antibody Titers in Renal Transplantation
Abstract
Desensitization strategies for ABO-incompatible renal transplants with plasma exchange (PE) or specific immunoadsorption (IA) decrease immunoglobulin levels. After recent measles outbreak and decreasing vaccination rates, we studied the impact of apheresis on anti-measles antibodies. Anti-measles antibodies were measured before desensitization, before transplantation and during followup in 12 patients with ABO incompatibility (2x PE only, 8x IA only, and 2x IA and PE) and 3 patients with donor-specific HLA antibodies (all PE). Patients received rituximab, IVIG, and standard immunosuppressive therapy. All patients had detectable anti-measles antibodies before desensitization (mean 3238 mU/l, range 560-8100). After 3-6 PE sessions, titers decreased significantly to 1710 mU/l (P < 0.05), in one patient to nondetectable values, while IA only maintained protective titers. After a median followup of 64 days, anti-measles antibodies returned to baseline in all patients. Immunity against measles was temporarily reduced by apheresis but remained detectable in most patients at time of transplantation. Desensitization maintains long-term protective immunity against measles.
Figures


Similar articles
-
ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.Xenotransplantation. 2006 Mar;13(2):148-53. doi: 10.1111/j.1399-3089.2006.00280.x. Xenotransplantation. 2006. PMID: 16623810
-
Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.Transplant Proc. 2013 May;45(4):1423-6. doi: 10.1016/j.transproceed.2013.01.081. Transplant Proc. 2013. PMID: 23726587
-
Therapeutic apheresis in ABO-incompatible kidney and liver transplantation: A single-center experience of 50 patients.Ther Apher Dial. 2021 Feb;25(1):103-117. doi: 10.1111/1744-9987.13495. Epub 2020 Apr 19. Ther Apher Dial. 2021. PMID: 32266793
-
Therapeutic apheresis in renal transplantation; current practices.J Clin Apher. 2014 Aug;29(4):206-10. doi: 10.1002/jca.21330. Epub 2014 May 27. J Clin Apher. 2014. PMID: 24863952 Review.
-
Current protocols and outcomes of ABO-incompatible kidney transplantation.World J Transplant. 2020 Jul 29;10(7):191-205. doi: 10.5500/wjt.v10.i7.191. World J Transplant. 2020. PMID: 32844095 Free PMC article. Review.
Cited by
-
Fatal Pneumococcus Sepsis after Treatment of Late Antibody-Mediated Kidney Graft Rejection.Case Rep Nephrol. 2018 Feb 28;2018:1415450. doi: 10.1155/2018/1415450. eCollection 2018. Case Rep Nephrol. 2018. PMID: 29682370 Free PMC article.
References
-
- Flint SM, Walker RG, Hogan C, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. American Journal of Transplantation. 2011;11(5):1016–1024. - PubMed
-
- Habicht A, Bröker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients—a single centre experience. Nephrology Dialysis Transplantation. 2011;26(12):4124–4131. - PubMed
-
- Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation. 2009;87(8):1246–1255. - PubMed
-
- Padmanabhan A, Ratner LE, Jhang JS, et al. Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience. Transplantation. 2009;87(12):1889–1896. - PubMed
-
- Tobian AAR, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion. 2008;48(11):2453–2460. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials